芪蓉润肠口服液治疗化疗后便秘疗效观察  

Clinical observation of Qirong Runchang Oral Liquid in the treatment of chemotherapy-induced constipation

作　　者：任芳[1] 王海明[1] 冯宇[1] 崔艺馨[1] 王茂云[1] 李绍旦[1] 

机构地区：[1]解放军总医院中医院,北京100853

出　　处：《北京中医药》2017年第10期897-899,共3页Beijing Journal of Traditional Chinese Medicine

基　　金：军队中医药科研专项课题(10ZYZ241)

摘　　要：目的观察芪蓉润肠口服液治疗化疗后便秘的临床效果。方法选取80例化疗患者,随机分为治疗组和对照组各40例。治疗组在化疗前1天开始给予口服芪蓉润肠口服液口服,对照组不常规服用通便药。比较2组治疗前后大便次数、大便困难程度等指标。结果治疗组便秘发生率12.5%,明显低于对照组的42.5%,2组比较差异有统计学意义(P<0.01)。治疗组主要疗效指标(大便次数及大便困难程度)及次要疗效指标(腹痛腹胀程度及恶心呕吐程度)明显优于对照组,2组差异有统计学意义(P<0.05)。结论芪蓉润肠口服液能有效防治化疗后便秘的发生率,减轻临床症状。Objective To observe the effect of Qirong Runchang 0ral Liquid on hemotherapy-induced constipation. Methods A total of 80 chemotherapy patients were randomized into two groups of 40 patients each. The treatment group began to take Qirong Runchang Oral Liquid one day before chemotherapy. The control group did not take it. Then the times and difficulty of bowel movement were observed. Results The incidence rate of constipation was 12. 5% in the treatment group, which was obviously lower than 42. 5% in the control group, and the difference was statistically significant （P 〈 0. 01 ）. The other data （ including the times and difficulty of bowel movement） and other secondary data （severity of abdominal pain and distension, nausea and vomiting） of the treatment group was effectively improved than the control group, and the difference was statistically significant （ P 〈 0. 05 ）. Conclusion Qirong Runchang Oral Liquid could effectively prevent chemotherapy-induced constipation and reduce some clinical symptoms.

关 键 词：芪蓉润肠口服液 中药 化疗 便秘 

分 类 号：R256.35[医药卫生—中医内科学]